ArticleCancer causes & control : CCC2026
Perspectives on GUIDE (Guiding participation toward understanding, inclusion, diversity, and equity for cancer trials): a clinical trial access intervention.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundWe sought to examine key patient and provider perspectives to develop GUIDE (Guiding participation toward Understanding, Inclusion, Diversity, and Equity for Cancer Clinical Trials), an intervention aimed to improve access to clinical trials through reimbursement of trial-related out-of-pocket costs and navigation. We sought patient and provider perspectives to optimize future GUIDE implementation.
methodsStudy team members conducted semi-structured 1:1 qualitative interviews with oncology patients (n = 20) and providers (n = 20) to identify influences on clinical trial participation and GUIDE acceptability, appropriateness, and feasibility. Data were analyzed using a deductive, rapid framework analysis. We applied a Consolidated Framework for Implementation Research and constructs of Proctor's taxonomy of implementation outcomes to organize themes and inform the development of GUIDE.
resultsPatients reported clinical trial-related expenses as significant barriers for trial participation. Providers unanimously found GUIDE acceptable, appropriate, and feasible. Participants indicated program success would depend on establishing clarity around reimbursement and the role of the trial navigator ('Guide') within an existing multidisciplinary team and equipping the Guide with skills and affect to build trust with patients.
conclusionHealth-related social needs (HRSN) are a critical influence on trial participation. Providers perceived the GUIDE program has potential to address HRSN and enhance trial diversity. For successful implementation, clear reimbursement protocols and infrastructure, integration of the Guide as part of the care team, and training for the Guide to screen for HRSN and connect patients to trial/institutional resources are needed. IMPACT: We report patient and provider-identified elements critical for future trial navigator programs.
Indexed as
Identifiers
41546729What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.